KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Nektar Therapeutics (NKTR) Operating Expenses (2016 - 2025)

Nektar Therapeutics (NKTR) has 16 years of Operating Expenses data on record, last reported at $86.8 million in Q3 2025.

  • For Q3 2025, Operating Expenses rose 48.37% year-over-year to $86.8 million; the TTM value through Sep 2025 reached -$5.5 million, down 102.82%, while the annual FY2024 figure was $37.4 million, 89.43% down from the prior year.
  • Operating Expenses reached $86.8 million in Q3 2025 per NKTR's latest filing, up from $4.1 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $174.4 million in Q2 2022 and bottomed at -$151.4 million in Q4 2024.
  • Average Operating Expenses over 5 years is $79.1 million, with a median of $74.5 million recorded in 2022.
  • Peak YoY movement for Operating Expenses: tumbled 363.77% in 2024, then surged 683.07% in 2025.
  • A 5-year view of Operating Expenses shows it stood at $137.9 million in 2021, then tumbled by 45.99% to $74.5 million in 2022, then decreased by 22.95% to $57.4 million in 2023, then crashed by 363.77% to -$151.4 million in 2024, then skyrocketed by 157.3% to $86.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Operating Expenses were $86.8 million in Q3 2025, $4.1 million in Q2 2025, and $55.0 million in Q1 2025.